Literature DB >> 15967544

Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.

Jay S Dela Cruz1, Sherie L Morrison, Manuel L Penichet.   

Abstract

In the present study, we demonstrate that a physical association between the extracellular domain of human HER2/neu receptor (ECDHER2) plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) was required to elicit the most effective anti-tumor immune response against a syngeneic tumor expressing rat HER2/neu. Immune effectors including CD4+, CD8+, and NK cells contributed to protection against tumor growth. Vaccinated B-cell deficient mice did not elicit tumor protection, suggesting a critical role for B-cells in a protective immune response. These results provide insights into the mechanisms responsible for the protective tumor immunity elicited when antibody-(IL-2 or GM-CSF) are used as enhancers of vaccines targeting tumor antigens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15967544     DOI: 10.1016/j.vaccine.2005.04.041

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

2.  Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model.

Authors:  Nafiseh Pakravan; Zuhair Mohammad Hassan
Journal:  Cell Stress Chaperones       Date:  2011-02-26       Impact factor: 3.667

3.  Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model.

Authors:  Nafiseh Pakravan; Ladan Langroudi; Monire Hajimoradi; Zuhair Mohammad Hassan
Journal:  Cell Stress Chaperones       Date:  2010-06-12       Impact factor: 3.667

4.  Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.

Authors:  Hui Ding; Gustavo Helguera; José A Rodríguez; Janet Markman; Rosendo Luria-Pérez; Pallavi Gangalum; Jose Portilla-Arias; Satoshi Inoue; Tracy R Daniels-Wells; Keith Black; Eggehard Holler; Manuel L Penichet; Julia Y Ljubimova
Journal:  J Control Release       Date:  2013-06-12       Impact factor: 9.776

5.  4H12, a Murine Monoclonal Antibody Directed against Myosin Heavy Chain-9 Expressed on Acinar Cell Carcinoma of Pancreas with Potential Therapeutic Application

Authors:  Sima Balouchi-Anaraki; Simin Ahmadvand; Akbar Safaei; Abbas Ghaderi
Journal:  Iran Biomed J       Date:  2021-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.